Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Mcdonald Capital Investors Inc. CA

Mcdonald Capital Investors Inc. CA trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 172,649 shares of the biopharmaceutical company’s stock after selling 20,389 shares during the period. Regeneron Pharmaceuticals comprises about 10.7% of Mcdonald Capital Investors Inc. CA’s portfolio, making the stock its 2nd largest position. Mcdonald Capital Investors Inc. CA’s holdings in Regeneron Pharmaceuticals were worth $130,915,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $5,682,636,000. Legal & General Group Plc bought a new position in Regeneron Pharmaceuticals in the second quarter worth approximately $473,872,000. Bank of New York Mellon Corp bought a new position in Regeneron Pharmaceuticals in the second quarter worth approximately $472,950,000. Deutsche Bank AG bought a new position in Regeneron Pharmaceuticals in the second quarter worth approximately $323,249,000. Finally, Man Group plc bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $272,460,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 1.0%

NASDAQ:REGN opened at $816.10 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $591.52 and a 12 month high of $859.34. The firm has a fifty day simple moving average of $791.66 and a 200-day simple moving average of $737.08. The company has a market capitalization of $84.02 billion, a P/E ratio of 20.17 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. During the same period last year, the firm earned $12.81 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 16.7% compared to the same quarter last year. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were given a dividend of $0.94 per share. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the sale, the director owned 603 shares in the company, valued at approximately $512,550. This represents a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 8,093 shares of company stock worth $6,506,845. 6.97% of the stock is owned by insiders.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron extended its agreement with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to supply additional doses of Inmazeb, its Ebola treatment. The extension adds approximately $270 million in value and supports near-term revenue visibility. Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb for U.S. Preparedness
• Positive Sentiment: Strong third-quarter results from partner Kiniksa highlighted growing demand and blockbuster potential for Arcalyst, which is partnered with Regeneron. The update may reinforce expectations for increased royalty or collaboration-related contributions. Kiniksa jumps as Q3 results show blockbuster prospects for Regeneron-partnered Arcalyst
• Positive Sentiment: Regeneron released nearly four years of survival-benefit data for Libtayo, its cancer immunotherapy. Durable efficacy could support the drug’s commercial positioning and future adoption. Regeneron Pharmaceuticals Posts Nearly Four Years of Survival Benefit Data for Libtayo
• Neutral Sentiment: Analysts expect third-quarter earnings of approximately $16.19 per share, with results due October 30. Investors are also focused on Regeneron recording its full share of Dupixent profits with Sanofi for the first time, a potentially significant earnings catalyst but one already receiving attention ahead of the report. Regeneron Q3 earnings preview
• Neutral Sentiment: Recent commentary describes REGN as an increasingly diversified investment and a strong value stock. Reported short interest of zero shares provides no meaningful bearish signal, although the figure may reflect a data-reporting issue rather than actual market positioning. Has Regeneron Stock Become a Different Bet?

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Cantor Fitzgerald upped their price objective on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, September 21st. TD Cowen boosted their target price on shares of Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the stock a “buy” rating in a report on Wednesday, October 21st. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a report on Tuesday, July 7th. Finally, Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $846.28.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.